Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

tislelizumab 3Paclitaxel 3Nivolumab 3pembrolizumab 2atezolizumab 2Docetaxel 2ulocuplumab 1tazemetostat 1tazarotene 1seviteronel 1rucaparib 1romiplostim 1phosphorylethanolamine 1pertuzumab 1neratinib 1magrolimab 1fluzoparib 1fludarabine 1epacadostat 1durvalumab 1camrelizumab 1Trastuzumab 1Sunitinib 1Poly(ADP-ribose) Polymerase Inhibitors 1LY2510924 1EC145 1Cyclophosphamide 1CH5183284 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumor × fludarabine × Clear all
NCT03139370 2023-08-25

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Gilead Sciences

Phase 1 Terminated
16 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡